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Summary: Neuron-specific enolase and carcino-embryonic antigen were quantified simultaneously in sera of
135 patients attending the Department of Respiratory Diseases for diagnostic bronchoscopy. Fifteen small
cell lung carcinomas, 24 non-small cell lung carcinomas and 96 benign pulmonary diseases were investigated.
Lung biopsies or bronchial washings were obtained from about 75% of the patients, including all patients
with neoplastic diseases. Serum neuron-specific enolase was measured by a recently introduced enzyme-
immuno assay (WaKo NS-Enolase EIA-II testkit). The results obtained with this kit were similar to those
based on RIA assays.
Receiver Operating Characteristic curves (ROC curves) were constructed for comparison of the discriminating
ability of neuron-specific enolase and carcino-embryonic antigen in small cell lung carcinomas and non-small
cell lung carcinomas. For small cell lung carcinomas the sensitivity and the specificity of neuron-specific
enolase (cutoff value: 10 μg/l) were 87% and 88%, respectively, and for carcino-embryonic antigen values
60% and 77% were obtained. There was no correlation between neuron-specific enolase and carcino-embryonic
antigen in small cell lung carcinoma patients. The diagnostic value of neuron-specific enolase and carcino-
embryonic antigen in non-small cell lung carcinomas is illustrated by sensitivities of 13% and 58%, respectively.
An extensive literature survey is included to allow comparison with other studies. The use of ROC curves is
recommended for the determination of optimal cutoff values for the assays employed.
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a group of 135 patients presented to the Department
of Respiratory Diseases for diagnostic bronchoscopy.
Carcino-embryonic antigen was also determined in
the serum samples. Receiver Operating Characteristic
curves (ROC curves; 6, 7) were used to compare the
value of neuron-specific enolase and carcino-embry-
onic antigen for the diagnosis of small cell lung car-
cinomas and non-small cell lung carcinomas, and to
optimize the cutoff levels.
Materials and Methods
Patients
A total of 135 patients, attending the Department of Respira-
tory Diseases of the De Wever Hospital for diagnostic bron-
choscopy, participated in this study. Biopsies or bronchial wash-
ings were obtained from about 75% of these patients, including
all with apparent bronchoscopic abnormalities. Histological
and cytological examinations performed by the Department of
Pathology diagnosed small cell lung carcinomas (10 limited and
5 extended cases) or non-small cell lung carcinomas. Patients
were classified in one of the categories, small cell lung carci-
nomas (n = 15), non-small cell lung carcinomas (n = 24) or
benign pulmonary diseases (n = 96). Serum samples were ob-
tained before the start of treatment. A number of small cell
lung carcinoma patients was followed during chemotherapy,
and serum samples were obtained two days before onset of the
chemotherapy cycles.
Neuron-specific enolase analysis
Serum samples, free of haemolysis, were stored at — 20 °C until
analysis. Neuron-specific enolase was quantified with the
WaKO NS-Enolase (EIA)-II testkit from Amano Pharmaceut-
ical Co (Distributor WaKo Pure Chemical Ind. Ltd., Osaka,
Japan; Code No. 991-20001). In brief, neuron-specific enolase
is bound to polyclonal rabbit anti-bovine neuron-specific eno-
lase antibody immobilized to polystyrene beads. A sandwich is
formed with -.D-galactosidase-labelled monoclonal murine
anti-neuron-specific enolase. After washing, the release of chlo-
rophenol red from chlorophenol red- -D-galactopyranoside
was measured photometrically. The reported neuron-specific
enolase concentrations are the means of duplicate analyses.
Results
In our evaluation of the WaKo neuron-specific eno-
lase kit we found intra- and inter-run coefficients of
variation that agreed with those quoted by the man-
ufacturers data, i. e. about 3 to 7% within run and 4
to 7% between runs. The analytical range is 1.7 to
135.0 μg/l. Higher concentrations were measured after
dilution of the sample with 9 g/1 saline solution. The
results of the neuron-specific enolase analyses are
presented in figure 1. The mean neuron-specific eno-
lase concentration for 5 patients with extensive small
cell lung carcinomas was 88.2 μg/l. For limited small
cell lung carcinomas (n = 10) and for non-small cell
lung carcinomas (n = 24), the mean neuron-specific
enolase concentrations were 18.0 μg/l and 6.6 μg/l,
respectively.
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Fig. 1. Concentration of neuron-specific enolase in the sera of
patients with small cell lung carcinoma and non-small
cell lung carcinoma.
Carcino-embryonic antigen analysis
Serum samples, free of haemolysis, were stored at — 20 °C until
analysis. Carcino-embryonic antigen was quantified with the
Amerlite carcino-embryonic antigen assay from Amersham Int.,
Amersham, United Kingdom (Code LAN 01502150). This en-
hanced luminescence immunoassay uses a solid phase sheep
anti-carcino-embryonic antigen polyclonal antibody and a
mouse anti-carcino-embryonic antigen monoclonal antibody.
Quantification by luminescence is performed by means of per-
oxidase-labelled sheep anti-mouse antibody and "Signal re-
agent" in the Amerlite Analyser. Carcino-embryonic antigen
concentrations given are means of duplicate analyses.
Statistical analysis
Non-parametric tests were applied. The Wilcoxon two-sample
test was used for testing tumour-marker level differences in
patient subgroups. The Spearman rank correlation test was
used for testing correlation between neuron-specific enolase and
carcino-embryonic antigen concentrations.
The neuron-specific enolase levels in the pre-treatment
samples of the extended small cell lung carcinoma
group were significantly higher than in the limited
small cell lung carcinoma group according to the
Wilcoxon test (p < 0.01). We found no significant
difference between the levels of carcino-embryonic
antigen in the extended small cell lung carcinoma and
the limited small cell lung carcinoma group (Wilcoxon
test, ρ < 0.05).
Neither a positive nor a negative correlation could be
detected between the neuron-specific enolase and the
carcino-embryonic antigen levels in the sera of the
whole small cell lung carcinoma group (n = 15)
(Spearman rank test, ρ < 0.01). In order to compare
the discriminating abilities of neuron-specific enolase
and carcino-embryonic antigen, both for small cell
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lung carcinomas and non-small cell lung carcinomas,
ROC curves were constructed (figs. 2 and 3).
As shown by figure 2, neuron-specific enolase clearly
has advantages over carcino-embryonic antigen for
the detection of small cell lung carcinomas. Based on
the ROC curve an optimal cutoff value of 10 μg/l was
selected (asterisk in fig. 2). At this cutoff value the
sensitivity and specificity were 87% and 88%, respec-
tively. The maximal value for the sum of sensitivity
and specificity was about 180% for neuron-specific
enolase in small cell lung carcinomas. For carcino-
embryonic antigen the maximal sum was about 130%
in small cell lung carcinomas. The test efficiency for
neuron-specific enolase in small cell lung carcinoma
detection, defined as the number of true positives plus
the number of true negatives divided by the total
number of patients, was 89% at the cutoff value 10.0
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Fig. 2. Receiver operating characteristic (ROC) curves of neu-
ron-specific enolase (· — ·) and carcino-embryonic anti-
gen (o —o) for the diagnosis of small cell lung carci-
noma.
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Fig. 3. Receiver operating characteristic (ROC) curves of neu-
ron-specific enolase (· — ·) and carcino-embryonic an-
tigen (o —o) for the diagnosis of non-small cell lung
carcinoma.
As shown in figure 3, the measurement of serum
neuron-specific enolase has no value for the detection
of non-small cell lung carcinomas, while carcino-em-
bryonic antigen has at least some discriminating abil-
ity. The maximal sum of sensitivity and specificity
was about 110% for neuron-specific enolase and
140% for carcino-embryonic antigen in non-small cell
lung carcinomas.
Follow up of patients
Longitudinal analyses were performed for a number
of small cell lung carcinoma patients. The results for
a case of limited small cell lung carcinoma and ex-
tended small cell lung carcinomas are presented. Pa-
tient F-L (fig. 4) was a 70 year old woman with the
diagnosis of limited small cell lung carcinoma, who
showed a partial remission after 5 chemotherapy
cycles. However, after 8 months a relapse was noticed
with cerebral and liver metastases and greatly in-
creased neuron-specific enolase levels.
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Fig. 4. Course of the serum neuron-specific enolase in patient
F-L (limited small cell lung carcinoma) after the initial
diagnosis.
Patient Μ (figure 5) was a 70 year old man with the
diagnosis of extended small cell lung carcinoma with
bone and liver metastases. Partial remission was seen
after 5 chemotherapy cycles. No tumour could be
found at bronchoscopy or X-thorax at 7 months after
the initial diagnosis. However, 3 months later a re-
lapse occurred with a sharp increase in neuron-specific
enolase.
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Fig. 5. Course of the serum neuron-specific enolase in patient
M (extended small cell lung carcinoma) after the initial
diagnosis.
Discussion
After the first report by Carney et al. (1) on the
diagnostic benefits of neuron-specific enolase in small
cell lung carcinomas, a number of studies have been
performed on this subject. In most studies RIA meth-
ods have been employed for the neuron-specific en-
olase analysis. In table 1 a literature survey (9 — 22)
is presented with emphasis on serum neuron-specific
enolase in small cell lung carcinomas. The presence
of high neuron-specific enolase levels in neuroblas-
tomas and other malignancies (5, 8) is beyond the
scope of our study.
It can be seen from table 1 that neuron-specific eno-
lase is useful for detecting and monitoring small cell
lung carcinomas. A comparison of the various studies
is, however, difficult, due to differences in methods
and selection of cutoff values (range 6 — 20 μg/l).
Many authors used a cutoff value derived from the
"normal values" of a reference population: mean plus
two or three standard deviations. Other authors used
quite arbitrary levels. For example a 25 μg/l cutoff
value was chosen as a "more discriminative limit" (4,
9, 10).
Improvement of specificity inherently leads to a de-
creased sensitivity of the tumour marker, as shown
by ROC curves (6, 7). It must be kept in mind that
especially the specificity data are dependent on the
reference (control) group used, as demonstrated in
table 1. In our opinion it is preferable to consider a
random group of patients elected for bronchoscopy,
including possible lung-carcinomas as a reference for
evaluating neuron-specific enolase and small cell lung
carcinomas, instead of a group of healthy controls or
patients with unrelated diseases. In figure 2 all patients
without the diagnosis small cell lung carcinoma or
non-small cell lung carcinoma, served as the reference
group.
The optimal cutoff value for neuron-specific enolase,
defined as the highest level corresponding to non-
disease, was derived from figure 2 (10 μg/l). Although
our cutoff value was obtained by a completely differ-
ent approach, it is equal to the one used by Gerbitz
(17) and Tamura (22) for their RIA assays. In general
the cutoff values used in RIA methods are higher
than in El A methods (tab. 1). Methodological differ-
ences include the use of polyclonals versus monoclon-
als, or possibly measurement of the αγ-isoenzyme as
well as the γγ-isoenzyme (e. g. 1. c. (26)). The WaKo
kit is based on a monoclonal antibody specific for the
γγ-isoenzyme. The frequently used Pharmacia RIA
assay is based on polyclonal antibodies binding the
αγ as well as the γγ-isoenzyme.
Table 2 presents a survey of literature on serum car-
cino-embryonic antigen levels in small cell lung car-
cinomas and non-small cell lung carcinomas (11, 18,
22 — 25). As in the studies using neuron-specific eno-
lase, a comparison of data is difficult, owing to dif-
ferences in methods and selection of cutoff values.
From the ROC curve presented in figure 2 we derived
a 2.5 μg/l cutoff value, which is lower than in other
studies (tab. 2).
In our study the generally used tumour marker, car-
cino-embryonic antigen, appeared to be of less value
for small cell lung carcinomas than the more specific
marker, neuron-specific enolase (see fig. 2). Waalkes
(25) found that pretreatment carcino-embryonic an-
tigen levels generally showed a correlation with the
stage of the disease and "not uncommonly" rose at
the relapse. However, later studies favoured neuron-
specific enolase rather than carcino-embryonic anti-
gen for the detection and follow-up of small cell lung
carcinomas. The same conclusion can be drawn from
a comparison of the data in the tables 1 and 2.
It can be concluded from an extensive literature survey
that the results obtained with the WaKo kit for neu-
ron-specific enolase are very similar to those published
for RIA or other EIA methods. Neuron-specific en-
olase analysis is clearly superior to carcino-embryonic
antigen in the diagnosis of small cell lung carcinoma.
Extended small cell lung carcinoma corresponds to
significantly higher neuron-specific enolase levels than
limited small cell lung carcinoma. Neuron-specific
enolase measurements are useful in the follow-up of
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Tab. 1 . Survey of studies on serum neuron- specific enolase
small cell lung carcinomas (N-SCLC).
Study,
1st author
Adewole
(1987)
Akoun
(1985)
Anastasiades
(1986)
Ariyoshi
(1983)
Bork
(1988)
Carney
(1982)
Cooper
(1985)
Esscher
(1985)
Fishbach
(1986)
Fujita
(1987)
G er bit z
(1986)
Johnson
(1984)
Kalo
(1985)
Tflwwra
(1987)
Togawa
(1987)
Our study
Diagnosis
SCLC
lim. SCLC
ext. SCLC
SCLC
lim. SCLC
ext. SCLC
N-SCLC
SCLC
N-SCLC
SCLC
N-SCLC
SCLC
lim. SCLC
ext. SCLC
SCLC
lim. SCLC
ext. SCLC
SCLC
lim. SCLC
ext. SCLC
N-SCLC
SCLC
lim. SCLC
ext. SCLC
N-SCLC
SCLC
N-SCLC
SCLC
N-SCLC
SCLC
lim. SCLC
ext. SCLC
N-SCLC
SCLC
SCLC
SCLC
lim. SCLC
ext. SCLC
SCLC
N-SCLC
SCLC
N-SCLC
Cutoff
fog/l)
12.5
12.5
12.5
16
16
16
16
8.8
8.8
7.5
7.5
15
15
15
12
12
12
12.5
12.5
12.5
12.5
12
12
12
12
11
11
6
6
10
10
10
10
20
12
10
10
10
11
11
10
10
Sensitivity
(%)
65
0
76
65
38
82
14
100
0
65
11
40
14
72
69
39
88
77
66
87
17
85
71
98
25
86
20
78
25
100
100
100
17
73
89
58
38
65
83
28
87
13
cases
13/20
0/3
13/17
28/43
6/16
22/27
2/14
7/7
0/9
13/20
6/54
10/24
2/14
8/11
65/94
15/38
49/56
59/77
25/38
34/39
16/94
88/103
34/48
54/55
13/51
6/7
3/15
14/18
15/60
27/27
8/8
19/19
5/29
68/93
8/9
14/24
3/8
11/16
10/12
11/40
13/15
3/24
(NSE) in pretreatment small cell lung carcinomas (SCLC) and non-
Controls Specificity
(%)
Lymphomas and 100
non-lung carcinoma
Healthy adults 97
Healthy volunteers 100
Normal subjects 100
Healthy adults 100
Blood donors 94
Metastatic lung 78
tumours, benign
lung lesions, bron-
chopneumonias
Blood donors plus 99
healthy employees
Benign diseases of 82
lung/mediastinum
Blood donors 97
Benign lung lesions 95
Healthy subjects, 100
mainly blood donors
Healthy subjects 100
Healthy adults 100
Healthy subjects 100
100
Healthy adults 100
N-SCLC, pneumo- 88
nia, benign lung
diseases
cases
41/41
34/35
20/20
80/80
30/30
31/33
32/41
151/152)
138/169
115/119
38/40
100/100
20/20
20/20
33/33
18/18
25/25
107/135
Method
RIA (Pharmacia),
cutoff suggested
by manufacturer
EIA (Own method),
cutoff = mean plus
2 s. d. of controls
ELISA
(Own method),
cutoff = upper limit
normal range
EIA (Own method),
cutoff tentatively set
RIA (ace. to Paus),
cutoff = normal up-
per reference limit
RIA (Own method),
cutoff = mean plus
3 s.d. of controls
RIA (Pharmacia),
cutoff suggested
by manufacturer
RIA (Own method),
cutoff = mean plus
3 s. d. of controls
RIA (Pharmacia),
cutoff = mean plus
2 s. d. of controls
EIA (Own method),
cutoff = mean plus
3 s.d. of controls
RIA (Pharmacia)
cutoff was set at
10 μβ/1
NSE in plasma!
RIA (Pharmacia)
cutoff = mean plus
3 s. d. of controls
EIA, similar to
WaKo-kit
RIA (Eiken, Tokyo)
RIA (Eiken, Tokyo)
EIA (WaKo kit)
cutoff derived
from ROC curve
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Tab. 2. Survey of studies on serum carcino-embryonic antigen (CEA) in pretreatment small cell lung carcinomas (SCLC) and
non-small cell lung carcinomas (N-SCLC).
Study,
1st author
Adewole
(1987)
Ganz
(1987)
Jacques
(1988)
Krauss
(1981)
Tamura
(1987)
Waalkes
(1980)
Our study
Diagnosis
SCLC
SCLC
SCLC
lim. SCLC
ext. SCLC
SCLC
lim. SCLC
ext. SCLC
N-SCLC
SCLC
lim. SCLC
ext. SCLC
SCLC
lim. SCLC
ext. SCLC
SCLC
N-SCLC
Cutoff
OAg/1)
10
5
5
5
5
6.5
6.5
6.5
6.5
5
5
5
5
5
5
2.5
2.5
Sensitivity
(%)
53
48
44
39
44
40
24
62
50
29
13
38
48
21
61
60
58
Method
cases
8/15 RIA, Kemtek
23/48 RIA, Roche
84/193 El A, Abott
27/62
57/129
24/60
8/34
16/26
24/48
7/24 RIA, Dinabott
1/8
6/16
20/42 RIA,
3/14 ace. to Hansen
17/28
9/15 Enhanced Luminescence
14/24 Immunoassay, Amersham
the disease and the monitoring of the results of treat-
ment. The comparison of different studies is difficult,
owing to differences in methods, cutoff values and
reference groups.
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